Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00331149
Status:
COMPLETED
Last Update Posted:
2017-08-22
First Post:
2006-05-26
Brief Title:
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinsons
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomised Double-Blind Double-Dummy Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets REQUIP IR or Ropinirole Prolonged Release Tablets SKF-101468 in Advanced Stage Parkinsons Disease Subjects Who Are Not Adequately Controlled on L-dopa
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries The new prolonged release formulation allows the drug to be taken once a day rather than three times a day This study will also evaluate the side effects of the new prolonged release formulation of ropinirole
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None